Quantifying Uncertainty and Robustness in a Biomathematical Model Based Patient-Specific Response Metric for Glioblastoma

Glioblastomas, lethal primary brain tumors, are known for their heterogeneity and invasiveness. A growing literature has been developed demonstrating the clinical relevance of a biomathematical model, the Proliferation-Invasion (PI) model, of glioblastoma growth. Of interest here is the development of a treatment response metric, Days Gained (DG). This metric is based on individual tumor kinetics estimated through segmented volumes of hyperintense regions on T1-weighted gadolinium enhanced (T1Gd) and T2-weighted magnetic resonance images (MRIs). This metric was shown to be prognostic of time to progression. Further, it was shown to be more prognostic of outcome than standard response metrics. While promising, the original paper did not account for uncertainty in the calculation of the DG metric leaving the robustness of this cutoff in question. We harness the Bayesian framework to consider the impact of two sources of uncertainty: 1) image acquisition and 2) interobserver error in image segmentation. We first utilize synthetic data to characterize what non-error variants are influencing the final uncertainty in the DG metric. We then consider the original patient cohort to investigate clinical patterns of uncertainty and to determine how robust this metric is for predicting time to progression and overall survival. Our results indicate that the key clinical variants are the time between pre-treatment images and the underlying tumor growth kinetics, matching our observations in the clinical cohort. Finally, we demonstrated that for this cohort there was a continuous range of cutoffs between 94 and 105 for which the prediction of the time to progression and was over 80% reliable. While further validation must be done, this work represents a key step in ascertaining the clinical utility of this metric.

[1]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[2]  Kristin R. Swanson,et al.  Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. , 2013, Cancer research.

[3]  K. Swanson,et al.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.

[4]  K. R. Swanson,et al.  From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine , 2013, Front. Oncol..

[5]  D. Silbergeld,et al.  Isolation and characterization of human malignant glioma cells from histologically normal brain. , 1997, Journal of neurosurgery.

[6]  Kristin R. Swanson,et al.  Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas , 2014, PloS one.

[7]  Kristin R. Swanson,et al.  Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice , 2015, Bulletin of mathematical biology.

[8]  Leland S. Hu,et al.  Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival. , 2018, JCO clinical cancer informatics.

[9]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[10]  David Basanta,et al.  Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. , 2014, Neuro-oncology.

[11]  Kristin R. Swanson,et al.  Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric , 2013, PloS one.

[12]  Nicholas Ayache,et al.  MRI Based Bayesian Personalization of a Tumor Growth Model , 2016, IEEE Transactions on Medical Imaging.

[13]  E. Mandonnet,et al.  Surgical Decision Making From Image‐Based Biophysical Modeling of Glioblastoma: Not Ready for Primetime , 2017, Neurosurgery.